About: Tratamiento antigripal: fármacos actualmente utilizados y nuevos agentes en desarrollo

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tratamiento antigripal: fármacos actualmente utilizados y nuevos agentes en desarrollo Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tratamiento antigripal: fármacos actualmente utilizados y nuevos agentes en desarrollo
Creator	Amarelle, Luciano Lecuona, Emilia Sznajder, Jacob
Source	Elsevier; Medline; PMC
abstract	Resumen La gripe es una enfermedad contagiosa altamente prevalente y con significativa morbimortalidad. El tratamiento disponible con fármacos antivirales, de ser administrado de forma precoz, puede reducir el riesgo de complicaciones severas; sin embargo, muchos tipos de virus desarrollan resistencia a estos fármacos, reduciendo notablemente su efectividad. Ha habido un gran interés en el desarrollo de nuevas opciones terapéuticas para combatir la enfermedad. Una gran variedad de fármacos han demostrado tener actividad antiinfluenza, pero aún no están disponibles para su uso en la clínica. Muchos de ellos tienen como objetivo componentes del virus, mientras que otros son dirigidos a elementos de la célula huésped que participan en el ciclo viral. Modular los componentes del huésped es una estrategia que minimiza el desarrollo de cepas resistentes, dado que estos no están sujetos a la variabilidad genética que tiene el virus. Por otro lado, la principal desventaja es que existe un mayor riesgo de efectos secundarios asociados al tratamiento. El objetivo de la presente revisión es describir los principales agentes farmacológicos disponibles en la actualidad, así como los nuevos fármacos en estudio con potencial beneficio en el tratamiento de la gripe. Abstract Influenza is a very common contagious disease that carries significant morbidity and mortality. Treatment with antiviral drugs is available, which if administered early, can reduce the risk of severe complications. However, many virus types develop resistance to those drugs, leading to a notable loss of efficacy. There has been great interest in the development of new drugs to combat this disease. A wide range of drugs has shown anti-influenza activity, but they are not yet available for use in the clinic. Many of these target viral components, which others are aimed at elements in the host cell which participate in the viral cycle. Modulating host components is a strategy which minimizes the development of resistance, since host components are not subject to the genetic variability of the virus. The main disadvantage is the risk of treatment-related side effects. The aim of this review is to describe the main pharmacological agents currently available and new drugs in the pipeline with potential benefit in the treatment of influenza.
has issue date	2017-01-31(xsd:dateTime)
bibo:doi	10.1016/j.arbres.2016.07.004
bibo:pmid	27519544
has license	els-covid
sha1sum (hex)	4e261c16f731485ca6c09dec03daa029787a69d4
schema:url	https://doi.org/10.1016/j.arbres.2016.07.004
resource representing a document's title	Tratamiento antigripal: fármacos actualmente utilizados y nuevos agentes en desarrollo
has PubMed Central identifier	PMC6889083
has PubMed identifier	27519544
schema:publication	Archivos de Bronconeumología
resource representing a document's body	covid:4e261c16f731485ca6c09dec03daa029787a69d4#body_text
is schema:about of	named entity 'DEVELOPMENT' named entity 'Development' named entity 'TREATMENT' named entity 'INFLUENZA' covid:arg/4e261c16f731485ca6c09dec03daa029787a69d4 named entity 'USED' named entity 'LINE' named entity 'DEL' named entity 'CURRENTLY' named entity 'DRUGS' named entity 'ART' named entity 'EL 2' named entity 'MAYO' named entity 'Historia' named entity 'el 9' named entity 'el 10' named entity 'Influenza Treatment' named entity 'influenza' named entity 'la entrada' named entity 'oseltamivir' named entity 'influenza' named entity 'zanamivir' named entity 'zanamivir' named entity 'Relenza' named entity 'La HA' named entity 'origen' named entity 'influenza' named entity 'modesto' named entity 'influenza' named entity 'PA 103' named entity 'puede ser' named entity 'influenza' named entity 'cepas' named entity 'Arbidol' named entity 'altera' named entity 'la liberación' named entity 'cepas' named entity 'esta' named entity 'Las guías' named entity 'la red' named entity 'primera línea' named entity 'oseltamivir' named entity 'influenza' named entity 'la HA' named entity 'influenza' named entity 'cepas' named entity 'influenza' named entity 'arbidol' named entity 'Como' named entity 'influenza' named entity 'influenza' named entity 'H5N1' named entity 'vacuna' named entity 'MAPK' named entity 'herpes virus' named entity 'arbidol' named entity 'oseltamivir' named entity 'La resistencia' named entity 'H1N1' named entity 'influenza' named entity 'influenza' named entity 'influenza' named entity 'nuevas generaciones' named entity 'influenza' named entity 'influenza' named entity 'H1N1' named entity 'influenza' named entity 'reovirus' named entity 'peramivir' named entity 'zanamivir' named entity 'oseltamivir' named entity 'influenza' named entity 'la respuesta' named entity 'vaccinia virus' named entity 'resistencia' named entity 'oseltamivir' named entity 'influenza' named entity 'influenza' named entity 'influenza'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software